Genetic changes within DNA may signal the progression of certain blood cancers, such as myeloproliferative neoplasms (MPNs), years before these shifts are detectable through routine blood tests, according to new research published in the journal Cancer Discovery. The study followed 30 individuals diagnosed with MPNs, a group of blood cancers characterized by the overproduction of blood cells by the bone marrow.
Researchers monitored DNA in the patients' blood and bone marrow, looking for genetic alterations associated with disease stability or progression to more advanced conditions like myelofibrosis or acute myeloid leukemia (AML). The findings indicate that patients whose MPNs remained stable often exhibited consistent DNA patterns without significant cancer-related genetic changes. Conversely, patients whose disease worsened frequently showed accumulating DNA alterations years before these progressions were evident in standard blood tests.
In some cases, the development of acute myeloid leukemia appeared to stem from separate groups of abnormal blood cells, a distinction also observed in patients who developed myelofibrosis. The study also noted that common medications used to manage MPNs, such as hydroxyurea and azacitidine, leave recognizable DNA alteration patterns. However, there was no evidence linking these drugs directly to leukemia development.
A subset of participants with a condition generally classified as a blood cancer, triple-negative essential thrombocythemia, showed no detectable genetic signs of cancer in their samples. This finding raises the possibility that some patients diagnosed with this condition may not have malignant disease and might not require long-term treatment.
Abhishek Chilkulwar, M.D., an oncologist at Orlando Health, who was not involved in the study, described the findings as a significant insight into the potential for precision medicine in blood cancer care. He noted that the research demonstrates how DNA changes could potentially predict the future course of these cancers a decade or more before clinical symptoms appear. Chilkulwar suggested that periodic DNA re-testing could provide doctors with an early indication of disease progression, allowing for closer monitoring and potentially more frequent clinical evaluations.
He cautioned, however, that in the near term, these genetic insights would likely lead to closer monitoring rather than immediate treatment changes. While the long-term goal may involve developing targeted therapies based on specific mutations, the immediate application would focus on earlier detection of risk for more attentive clinical management. Chilkulwar emphasized that this early genetic warning would not be a basis for initiating serious procedures like stem cell transplants, which are reserved for patients who have already progressed to myelofibrosis or AML.
The study's authors acknowledged limitations, including a small sample size, and noted that their findings establish associations rather than definitive cause-and-effect relationships. Future research may focus on pairing early genetic detection with drugs designed to act on specific mutations, with the aim of preventing or delaying disease progression.